Article

[Pancreatic resection for metastatic tumors to the pancreas].

Dept. of Hepatobiliary and Pancreatic Surgery, Kanagawa Cancer Center.
Gan to kagaku ryoho. Cancer & chemotherapy 11/2011; 38(12):2068-70. DOI: 10.1002/jso.10262
Source: PubMed

ABSTRACT We report 3 cases of resectable pancreatic metastasis. CASE 1: A 76-year-old woman was followed after nephrectomy for renal cell carcinoma for 13 years. CT examination demonstrated a high vascular lesion in the pancreatic body and tail. We conducted distal pancreatectomy and diagnosed with metastatic tumor from renal cell carcinoma. She died of liver metastasis 8 years after pancreatic resection. CASE 2: A 64-year-old man, who had undergone right lower lobectomy for lung cancer a year ago, was found to have a mass in the pancreatic tail. We performed distal pancreatectomy and diagnosed with metastatic tumor from lung cancer. He died of lung metastasis 12 months after pancreatic resection. CASE 3: A 62- year-old woman, who had undergone left nephrectomy for renal cell carcinoma 3 years ago, was found to have a mass in the pancreatic body. With a diagnosis of metastatic pancreatic tumor from renal cell carcinoma, distal pancreatectomy was done. She died of liver and lung metastases 15 months after pancreatic resection. Long-term survival can be achieved in patients undergoing a pancreatic standard resection including lymphadenectomy for isolated metastasis from nonpancreatic sites.

0 Bookmarks
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objectives. Pancreatic metastasis from osteosarcoma and Ewing sarcoma is extremely rare. Differential diagnosis with primary pancreatic carcinoma is crucial before any treatment, but may be very difficult. Material and methods. We searched for and reviewed the cases reported in the English literature. Results. Twelve cases were identified, including nine osteosarcoma patients and three Ewing sarcoma cases. The median time between the sarcoma diagnosis and that of pancreatic metastasis was 3 years. In most of the cases, the pancreatic relapse followed or was associated with relapse(s) in one or more sites. Two out of eight patients with available follow-up were alive without disease 6+ and 11+ months after complete surgical removal, whereas five patients died from disease. Histological diagnosis was obtained before surgery in only five cases using percutaneous Tru-Cut biopsy in three cases and endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNAB) in the two most recent ones. Conclusions. Osteosarcoma or Ewing sarcoma metastasis should be included in the differential diagnosis of pancreatic solid lesion, particularly in patients with a primary tumor. In this context, EUS and EUS-FNAB are reliable methods for the pre-operative diagnosis and should thus be discussed before any therapeutic decision.
    Scandinavian Journal of Gastroenterology 08/2012; · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: The pancreas is a rare target for metastasis from other primary cancers, but pancreatic metastasis play a role in the diagnostic workup of patients with pancreatic tumors, especially in patients with a history of renal cell carcinoma (RCC). Methods: Between October 2001 and June 2004 data from 601 patients undergoing pancreatic resection were entered prospectively in a database and were analyzed for metastasis into the pancreas from RCC. Results: Fifteen patients with metastasis to the pancreas from RCC were identified. One patient showed metastatic disease at time of primary diagnosis. In 8 patients, the pancreas was the only site of metastasis, whereas in 7 patients, other organs, such as the thyroid gland, the lung, or the liver, were targets of metastasis, either metachronous or simultaneous at the time of pancreatic metastasis. The median interval between primary treatment of RCC and occurrence of pancreatic metastasis was 86 months (range, 0-258). Most patients were asymptomatic and diagnosed during standard tumor follow-up. So far, 14 patients remain alive with a median follow-up of 10 months. Conclusion: Pancreatic metastasis from RCC is rare but can occur even more than 20 years after primary tumor manifestation. Our results show that pancreatic resections for metastasis can be performed safely with a low rate of complications. Patients with a history of RCC should undergo a long-term follow-up to detect and evaluate for pancreatic metastases as well for metastasis to other organ sites.
    Pancreas 03/2005; 30(3):218-222. · 2.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Der Stellenwert der Resektion von Pankreasmetastasen ist bisher nicht hinreichend untersucht. Wir untersuchten unser Patientengut nach Pankreasresektionen bei Metastasen im Pankreas retrospektiv hinsichtlich des klinischen Verlaufes und des Langzeitüberlebens.Zwanzig Patienten wurden aufgrund von metastatischen Raumforderungen im Pankreas reseziert: Nierenzellkarzinom (n=9), Sigmakarzinom (n=1), malignes Schwannom (n=2), Leiomyosarkom (n=2) Teratokarzinom (n=1), Ösophaguskarzinom (n=1), Gallenblasenkarzinom (n=1), malignes Melanom (n=1), gastrointestinaler Stromatumor (n=1) sowie spindelzelliger mesenchymaler Tumor (n=1). Bei 6 Patienten wurde eine partielle Duodenopankreatektomie (Kausch-Whipple) durchgeführt, bei weiteren 6 eine pyloruserhaltende Pankreaskopfresektion. Acht Patienten erhielten eine Pankreaslinksresektion mit Splenektomie. Das 5-Jahres-Überleben für alle Patienten lag bei 61%, für Patienten mit Nierenzellkarzinom bei 100%.Resektionen von Metastasen im Pankreas können bei ausgewählten Patienten eine sinnvolle Therapieoption darstellen. Patienten mit Hypernephrommetastasen zeigen dabei nach Ausschluss weiterer Metastasen nach radikaler Resektion eine exzellente Prognose.
    Der Chirurg 01/2008; 79(3). · 0.52 Impact Factor